ARCHIVES

Revlimid Maintenance Therapy Delayed Progression by 90%

This article is from The Cancer Letter archive.

Vol. 34 No. 5 | May 27, 2011

Download PDF Visit The Full Archive

Related Articles

Drugs and Targets: Blincyto granted accelerated approval in R/R ALL

December 5, 2014

Hammer Gives $100,000 to Expand Rosenberg’s T-Cell Growth Factor Clinical Studies

March 1, 1985

Perifosine Increases PFS In Phase II Study

December 30, 2011

Nixon Resignation Won’t Hurt Cancer Program, Might Lead To More Money; Weinberger Stays

August 16, 1974

In Brief: Peter Vogt Names Bristol-Myers Winner; Other Awards: Koop, Weinberg, Wynder, Longmire

March 24, 1989

Tobacco Use Research Centers Funded

October 22, 1999